Compare ESTA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | MESO |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2018 | 2005 |
| Metric | ESTA | MESO |
|---|---|---|
| Price | $61.99 | $14.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $98.00 | $37.00 |
| AVG Volume (30 Days) | ★ 467.3K | 265.1K |
| Earning Date | 10-29-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,208,000.00 | N/A |
| Revenue This Year | $30.22 | $51.63 |
| Revenue Next Year | $24.46 | $63.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.49 | N/A |
| 52 Week Low | $47.23 | $11.89 |
| 52 Week High | $97.59 | $21.50 |
| Indicator | ESTA | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 55.05 |
| Support Level | $54.10 | $13.77 |
| Resistance Level | $67.75 | $16.06 |
| Average True Range (ATR) | 3.93 | 0.46 |
| MACD | 0.63 | 0.33 |
| Stochastic Oscillator | 41.24 | 71.76 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.